To assess the urinary markers of podocytic (nephrin) and tubulointerstitial damage (NGAL, KIM-1, albuminuria) levels in patients with atrial fibrillation (AF) and chronic kidney disease (CKD) stages 3 and 4 and to evaluate their relationship with bleedings during rivaroxaban treatment.
No takes yet. Share an insight, caveat, or question.
Shatalova et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: